Skip To Main Content
Kelsey Moroz on Muck Rack

Kelsey Moroz

Verified
New York
As seen in: Med Journal 360, Ophthalmology 360, Rare Disease 360, First Report Managed Care, CONQUER
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kelsey

Contact Kelsey, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mental health and peer support key to resilience in Alagille syndrome

|
By Kelsey Moroz Verified
| Med Journal 360 Verified
Mental and emotional health should be considered an essential part of care for individuals and families affected by Alagille syndrome (ALGS), according to Albert Freedman, PhD, who discussed the topic during his presentation, “Supporting the Emotional Health of Individuals and Families Affected by ALGS: Lessons Learned,” at the 12th International Symposium on Alagille Syndrome.
Open in Who Shared Issue with article?

Teprotumumab linked to improvements in proptosis and disease activity in thyroid eye disease

|
By Kelsey Moroz Verified
| Med Journal 360 Verified
Teprotumumab demonstrated effectiveness in a Japanese real-world cohort of patients with roid eye disease, while MRI findings showed that its effects on orbital fat and extraocular muscles differed from those of intravenous glucocorticoid therapy. The study included 18 patients initiating treatment with teprotumumab, and a historical cohort of 20 patients treated with intravenous glucocorticoids.
Open in Who Shared Issue with article?

FDA approves first ophthalmic bevacizumab for wet AMD

|
By Kelsey Moroz Verified
| Ophthalmology 360
The FDA approved the first ophthalmic formulation of bevacizumab for the treatment of wet AMD. The approval provides an FDA-approved bevacizumab developed specifically for the eye, replacing reliance on repackaged intravenous formulations. The product is expected to be available to eligible U.S. patients before year-end, supported by reimbursement and patient assistance programs.
Open in Who Shared View Duplicates (2) Issue with article?
See all 608 articles